297a.T
The company operates in the Food & Drug Retailing industry, generating revenue primarily through the sale of food and drug products to consumers.
Business. 297A.T is a food and drug retailer operating within the Consumer Non-Cyclicals sector. The company generates revenue through the sale of products in the food retail and distribution industry. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
297A.T is a food and drug retailer operating within the Consumer Non-Cyclicals sector. The company generates revenue through the sale of products in the food retail and distribution industry. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.
The company maintains a market price of 210.0 and a market cap of 14,494,020,240.0, with a price-to-earnings ratio of 6.32 and a price-to-book ratio of 1.0. The company's liquidity position is characterized by a current ratio of 0.74, indicating a potential liquidity risk. The company's free cash flow is 2,846,650,000.0, while its operating cash flow is 2,503,695,000.0.
In terms of profitability, the company's return on equity is 0.1579, and its return on assets is 0.0393. The company's operating income is 3,168,173,000.0, and its net income is 2,292,471,000.0. The company's gross profit is 31,434,625,000.0, which is a significant portion of its total revenue of 103,836,216,000.0.
The company's revenue is primarily concentrated in the Food & Drug Retailing segment, with no disclosed geographic breakdown. The company's total assets are 58,346,903,000.0, and its total liabilities are 43,828,710,000.0, with a debt-to-equity ratio of 1.79. The company's long-term debt is 25,974,272,000.0, and its cash and equivalents are 4,206,320,000.0.
The company's growth trajectory is reflected in its capital expenditure of -2,437,991,000.0 and its operating cash flow of 2,503,695,000.0. The company's free cash flow is 2,846,650,000.0, indicating a positive cash flow position. The company's revenue is expected to grow in the current fiscal year, with a positive outlook for the next fiscal year.
The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The company's key flags include a negative net cash position after subtracting total debt. The company's dilution potential is low, with no significant dilution sources identified. The company's risk score is moderate, with no immediate dilution pressure expected.
Recent events and filings indicate that the company has not disclosed any significant events or transcripts that would impact its financial position. The company's financial statements and disclosures are consistent with its current financial position and risk profile.
- The company has a strong price-to-earnings ratio of 6.32, indicating a potentially undervalued stock.
- The company's return on equity of 0.1579 suggests a solid profitability position.
- The company's liquidity position is a concern, with a current ratio of 0.74.
- The company's debt-to-equity ratio of 1.79 indicates a high level of leverage.
- The company's free cash flow of 2,846,650,000.0 supports its operational flexibility.
- margin_outlook_rationale: The company's gross profit margin is expected to remain stable due to consistent demand for food and drug products.
- rd_outlook_rationale: The company's research and development spending is not a significant factor in its operations.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 297A.T Market data — financials · 2026-05-26